Compare · LIVN vs NUWE
LIVN vs NUWE
Side-by-side comparison of LivaNova PLC (LIVN) and Nuwellis Inc. (NUWE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and NUWE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $3.51B, about 1128.9x NUWE ($3.1M).
- Over the past year, LIVN is up 71.1% and NUWE is down 97.2% - LIVN leads by 168.4 points.
- NUWE has been more active in the news (7 items in the past 4 weeks vs 1 for LIVN).
- LIVN has more recent analyst coverage (20 ratings vs 1 for NUWE).
- Company
- LivaNova PLC
- Nuwellis Inc.
- Price
- $64.18-1.47%
- $1.16-0.43%
- Market cap
- $3.51B
- $3.1M
- 1M return
- +1.42%
- +4.50%
- 1Y return
- +71.15%
- -97.24%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 1
- 7
- Recent ratings
- 20
- 1
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest LIVN
- Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
- SEC Form 4 filed by Tezel Ahmet
- SEC Form 4 filed by Poletti Franco
- SEC Form 4 filed by Makatsaria Vladimir
- SEC Form 4 filed by Shvartsburg Alex
- SEC Form 4 filed by Bolton Stephanie
- SEC Form 4 filed by Kozmina Natalia
- MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
- LivaNova to Announce First-Quarter 2026 Results
- LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
Latest NUWE
- Nuwellis Inc. filed SEC Form 8-K: Other Events
- Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
- Nuwellis Announces Aquadex Software Update
- Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum
- Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services
- Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory
- SEC Form DEFA14A filed by Nuwellis Inc.
- SEC Form DEF 14A filed by Nuwellis Inc.
- Amendment: Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone